Abstract:To the editor, We read the recent study by Moore et al.[1] reporting that compromised hepatic fatty acid oxidation (FAO) and mitochondrial turnover are closely related to NAFLD severity in obese patients. The article greatly increases our understanding of the role of mitochondria in the pathogenesis of NAFLD, but we still had some concerns about the results that require attention. First, mitochondrial homeostasis, a prerequisite for mitochondrial functions, is majorly orchestrated by mitochondrial biogenesis and mitophagy. The perturbation between mitochondrial biogenesis and mitophagy causes the dysfunction of the mitochondria pool, which results in less ATP production and more reactive oxygen species (ROS) generation.[2] Hepatic mitochondrial biogenesis, mitophagy, and dynamics of patients with B‐NASH and D‐NASH were impaired in the current study, which further contribute to round, swollen, hypodense mitochondria with loss of cristae. The declined ATP production and accumulated ROS generation are a sure result. However, the protein content of hepatic OXPHOS complexes did not differ across groups. At the same time, the whole‐liver antioxidant defense system markers of protein content are not declined. Altogether, it is hard to explain that the mitochondrial ATP and ROS generation were significantly changed. It is well known that mitochondrial superoxide generated from the electron leak from Complexes I and III of electron transport chain during ATP production, and dysfunctional complex I and III trigger more superoxide generation.[3] We think that it is necessary to provide evidence of complex I and III activity not only for the ROS accumulation but also for the less energetic metabolism. Second, peroxisome proliferator‐activated receptor‐gamma coactivator (PGC‐1α), a co‐activator of peroxisome proliferator‐activated receptor gamma (PPARγ), is considered the master transcriptional regulator of mitochondrial biogenesis, but it is not enough to indicate the mitochondrial biogenesis by itself. PGC‐1a interacts with different transcription factors participating in multiple cellular activities including mitochondrial biogenesis, adaptive thermogenesis, angiogenesis, regulation of tricarboxylic acid cycle, gluconeogenesis, FAO, and oxidative phosphorylation.[4] Therefore, the dramatic reduction of mitochondrial biogenesis needs more evidence to confirm. Mitochondrial transcription factor A and mitochondrial DNA copy represent the direct mitochondrial biogenesis and need to be further determined. It should be noticed that deficient mitophagy might lead to damaged mitochondria accumulation, contributing to mDNA copy increase. Finally, mitophagy, a specific autophagic elimination of mitochondria, shares the most of molecular mechanic machinery with autophagy; thus, the interpretation of mitophagy needs more careful review. However, the study only detected the protein content of BCL2/adenovirus E1B19 kDa‐interacting protein 3 (BINP3), Phosphatase and tensin homolog (PTEN)‐induced kinase 1 (PINK1), and Parkinson's disease protein (PARKIN) of hepatic mitochondria. In actuality, the accumulated P62 and LC3 on mitochondria are more important to mitophagic flux.[5] We recommend that the authors further detect the P62 and LC3 of hepatic mitochondria. Another question to be answered is why a low level of ethanol is a mitochondrial biogenesis activator. In conclusion, we agree with the investigators’ conclusion that compromised hepatic FAO and dysfunctional mitochondria are closely related to NAFLD severity in obese patients. However, further studies are required to determine the mitochondrial biogenesis, the mitophagy, and the Complexes’ activity alteration in obese patients with NAFLD. CONFLICT OF INTEREST Nothing to report.

Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease

Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity

Ketogenesis protects against MASLD-MASH progression through mechanisms that extend beyond overall fat oxidation rate

Unravelling the role of mitochondrial dysfunction in the switching towards progressive MASLD by exploiting an AMLN diet-fed mouse model

Letter to the Editor: Compromised Hepatic Mitochondrial Fatty Acid Oxidation and Reduced Markers of Mitochondrial Turnover in Human NAFLD

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches

Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease

Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function

Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals

Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment

Therapeutic management of metabolic dysfunction associated steatotic liver disease

Investigating the postprandial metabolic and inflammatory phenotypes of healthy subjects and patients with metabolic dysfunction-associated steatotic liver disease and metabolic-dysfunction associated steatohepatitis to understand disease progression

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic-Dysfunction Associated Liver Disease Progresses Independent of Weight in a Rodent Model

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease

Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation

Loss of TMEM55B modulates lipid metabolism through dysregulated lipophagy and mitochondrial function

Recent advances in age-related metabolic dysfunction-associated steatotic liver disease